Pfizer has IDA-supported facilities at five sites in Ireland that employ 3,500 people. It is the largest pharmaceutical sector investor and employer. From an initial investment of €10 million in 1969, Pfizer's total investment in Ireland now stands at nearly €8 billion.
GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions.
In 1997, Takeda, the largest pharmaceutical company in Japan, established a Formulation Plant in Bray, Wicklow, for the manufacture of three of the company’s blockbuster drugs (Prevacid, Blopress and Actos). The establishment of this facility was paramount to Takeda’s strategy in responding to expanding growth in the European and US markets. This plant has significantly expanded its operation since inception and operates on a 24 hour/7 day basis.
Merck & Co., New Jersey is a global research-driven pharmaceutical company and is the fifth largest pharmaceutical company in the world. Outside North America it is known as MSD.
A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.
Biotech & Biotech Partnerships.
Biotech & Medtech Partnerships.
Biotech & Medtech & Medical
Biotech & Health Systems Partnerships.
INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL)
Fri August 9, 2019 8:30 AM|Business Wire|About: GILD
-- Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks --
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)
Thu August 15, 2019 8:00 AM|Canada Newswire|About: GILD
MISSISSAUGA, ON, Aug. 15, 2019 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada)
In-licensing: through in-licensing partnerships with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring, we have quickly built our China Portfolio by acquiring multiple innovative clinical stage assets with favorable clinical safety and early efficacy data. In that respect, we are often considered an ideal China partner by our global partners because of our strong development capabilities and proven track record.
Out-licensing: the out-licensing deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In addition, we seek co-development opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have out-licensed three de-prioritized assets and initiated four co-development programs with partners such as ABL Bio, Everest Medicines and WuXi Biologics. The revenue we generated from out-licensing and co-development deals is expected to continue to grow as our pipeline progresses.
Our headquarters is based in Zhangjiang, Pudong, Shanghai. The Shanghai site has a state-of-the-art laboratory facility that hosts both our discovery unit and the CMC research unit (cell line and analytical development). There are also large open-office spaces hosting the R&D organization, the CMC department and the operation teams. Site address: Suites 802, 505, 702, West Tower, 88 Shangke Road, Pudong New District, Shanghai, China.
Copyright I-MAB Biopharma Co., Ltd. all rights reserved 2019
Switzerland is the world’s most-innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the 2019 edition of the Global Innovation Index (GII), which also identifies regional leaders India, South Africa, Chile, Israel and Singapore, with China, Vietnam and Rwanda topping their income groups.
Switzerland is the world’s most innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the GII 2019. https://www.wipo.int/global_innovation_index/en/2019/index.html
Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System
Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR
NEWS PROVIDED BY Varian Jul 25, 2019, 03:00 ET
PALO ALTO, Calif. and STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced that the Karolinska University Hospital Solna in Sweden is the first hospital in Scandinavia to deliver High Dose Rate (HDR) brachytherapy treatments using the new Bravos™ afterloader system
Karolinska University Hospital is one of Europe’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in development and medical break-throughs.
In 2018, the Asia-Pacific health tech industry had a record-breaking year in total funding, closing at $6.3 billion, making the Asia-Pacific health tech ecosystem the second largest in the world in value, behind only the United States. As the health tech boom surges in the Asia-Pacific, healthcare solutions geared towards medical diagnosis, health management, patient solutions, and population health management garnered multimillion-dollar deals.
Health tech may hold the promise of providing new inroads for the biggest healthcare challenges of our time. From patient care, to data management, personalized medicine and population health, Smart Healthcare tools including blockchain, AI, 3D printing, and wearables, may be the key that unlocks new advances that make a meaningful difference for people around the globe.
That’s why Johnson & Johnson Innovation - JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI), Janssen Korea Ltd. are launching the Seoul Innovation QuickFire Challenge in Smart Healthcare. Up to two innovators with the best idea, technology, or solution that aims to address a health need for the world's population will receive up to KRW150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub, and mentorship from experts at the Johnson & Johnson Family of Companies.
Up to KRW 150,000,000 (~ US $134,000)
Johnson & Johnson 2019 Q2 - Results - Earnings Call Slides
Jul. 16, 2019 9:35 AM ET Johnson & Johnson (JNJ)
The world’s largest JLABS and the first in Asia Pacific aims to support more than 50 life science start-ups from around the world with the hope to accelerate healthcare innovation in China and globally
SHANGHAI, June 27, 2019 — Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd.
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer
AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology
Johnson & Johnson and Boston University Announce a New Alliance Focused on Tackling Lung Cancer
Shanghai Lung Cancer Innovation QuickFire Challenge
"partnerships help foster a culture of entrepreneurship and innovation in the university community.”.
Bill Nygren Comments on Bristol-Myers Squibb = "The company’s two most valuable drugs Opdivo and Yervoy should continue to grow revenue as they maintain effectiveness with new tumor types. Bristol Myers Squibb also has the most new molecular agents and the highest number of combinations of agents in trials. Moreover, the company’s R&D and marketing prowess also make it a desired partner for promising academic and small biotech innovators.
Bill Nygren - Oakmark Fund manager - invested in 6.5 million shares of Bristol-Myers Squibb for an average price of $54.03 per share. The manager dedicated 1.85% of his equity portfolio to the position.
Ray Dalio - Bridgewater Associates also invested in Bristol-Myers during the quarter.
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Jeff Auxier comments on Merck = Merck beat estimates in the second quarter of 2018 with $10.5 billion in revenues and EPS of $1.06. They were buoyed in the quarter by their signature cancer drug KEYTRUDA which allows the body’s immune system to destroy cancerous cells by blocking a protective enzyme in cancer cells. Sales grew 89% in the quarter to $1.667 billion and are expected to continue to grow to upwards of $13 billion annually by 2026. Recently KEYTRUDA was approved in China and the EU for metastatic melanoma.
Jeff Auxier Comments on Biogen = Biogen saw revenues increase by 9% to $3.4 billion. Revenue growth was driven by Spinal Muscular Atrophy drug Spinraza which saw a 108% increase in revenue. Spinraza is Biogen’s fastest growing drug which they hope will be able to offset the slowing Multiple Sclerosis product line. Biogen presented the detailed results for the phase II trials of their Alzheimer’s drug BAN2401 on July 25th. The results of the trial were positive with tested patients showing 30% less cognitive decline over 18 months than those who received the placebo, but the presentation garnered a mixed reception and caused Biogen’s stock to fall 9% in after-hours trading. Earlier in July, Biogen announced that the trials of the drug were looking very positive without giving any details, and this announcement may have caused many to anticipate that the results would be better than what was ultimately shown. Currently, Biogen’s stock is hurting from the results announcement, but their outlook is still positive in the long-run due to the strength of their pipeline. Another Alzheimer’s drug in Biogen’s pipeline, Aducanumab, just finished its enrollment for two phase III trials. This drug has been regarded as more promising than BAN2401, and if it is successful Biogen will have the only drug in a $12 billion market.
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -Amgen (AMGN) announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S.and global markets.
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Merck Obtains Earlier FDA Approval For Expanded Label Of Keytruda In Front-Line Lung Cancer
First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC). XTANDI is now approved to treat another form of advanced prostate cancer. XTANDI is now approved to treat men with prostate cancer that no longer responds to treatment that lowers testosterone and has not spread to other parts of the body.
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer
Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treated
Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and...
Novartis Kisqali® now first and only CDK4/6 inhibitor that is indicated with fulvestrant as both initial or second-line treatment for postmenopausal women with HR+/HER2- advanced breast cancer
BIOGEN AND EISAI REPORT DATA FROM LONG-TERM EXTENSION PHASE 1B STUDY OF INVESTIGATIONAL ALZHEIMER’S DISEASE TREATMENT ADUCANUMAB
Study Shows Improved Quality of Life and Reduced Symptoms In Patients Treated with Medtronic Cryoballoon
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
Intuitive Submits New Robotic-Assisted Platform to FDA for Obtaining Lung Biopsies
Illumina Receives Approval of MiSeq™Dx System in China
FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
FDA APPROVES EYLEA® (AFLIBERCEPT) INJECTION SBLA IN WET AGE-RELATED MACULAR DEGENERATION
Celgene Announces Phase III ‘AUGMENT' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint
Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in A1C and a 30% lower rate of hypoglycaemic episodes after starting basal insulin
Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic and endocrine related disorders. The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™ (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome. INGREZZA (valbenazine) capsules was approved by the FDA on April 11, 2017 for the treatment of adults with tardive dyskinesia and is currently commercialized by Neurocrine in the United States.
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Dise
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China
PerkinElmer’s EUROIMMUN Receives FDA Clearance for ANCA IFA and EUROPLUS Granulocyte Mosaic™ assays using EUROPattern Microscope
Agilent Technologies Inc. (NYSE: A) announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors
Thermo Fisher Scientific Board Authorizes $2 Billion of Share Repurchases